ScripsAmerica Provides Highlights of Upcoming Presentation
Will Report Preliminary Fiscal 2014 Revenues of over $31 Million and Profitable Second Half of Year
Now Projecting First Quarter 2015 Net Income of over $400,000 on Revenues of more than $9.5 Million
TYSONS CORNER, Va.--(BUSINESS WIRE)--March 18, 2015--
ScripsAmerica, Inc. (OTCBB: SCRC), a leading provider of a range of specialty prescription and over the counter pharmaceuticals and medical supplies, today provided the investment community highlights of comments it will be making at the Wall Street Analyst Forum's 25th Annual Institutional Investor Conference about the Company's significantly improved financial results, outstanding growth of the specialty pharmacy business and rapid emergence of new revenue streams from diabetic medical supplies, PIMD International, Inc. and physician dispensing programs. This conference will be held at the University Club in New York, NY on Thursday, March 19, 2015.
-- The Company is currently projecting first quarter 2015 Net Income of over
$400,000 on revenue of over $9.5 million
-- The Company's preliminary financial reports indicate that revenue for the
year ended December 31, 2014 is expected to exceed $31 million
-- The Company's preliminary financial reports indicate that the Company
expects to report positive Net Income and EPS for the second half of 2014
-- As of December 31, 2014, it is anticipated that the Company will have
over $1.3 million in working capital, an approximately $3 million
improvement in liquidity over the course of fiscal 2104. In addition, the
Company has a $4 million working capital line of credit, providing all of
the liquidity and capital needed to execute its 2015 growth plan
-- The Company's PIMD International subsidiary has increased revenues from
$150,000 in January to $500,000 in February, with expectations that
revenues will remain at, if not exceed, February levels for the balance
of the year
-- The Company's newly launched diabetic medical supplies business has
enrolled over 700 patients, which will ramp a valuable new revenue stream
over the balance of the year
-- The Company has signed 2 Letters of Intent to purchase additional
pharmacies, which will supplement the revenues being generated by Main
Avenue Pharmacy
Mr. Schneiderman said, "Our goal is to generate value for our shareholders and the outstanding financial performance achieved in fiscal 2014, especially over the second half of the year, has created tremendous momentum heading into 2015, with current projections of a profitable first quarter of 2015. We have put in place a strategy that capitalizes on unique market niches where ScripsAmerica has a competitive advantage, and have built the infrastructure and management team that can effectively execute a plan to grow in these markets. While there will always be headwinds, because of our increasing financial strength and diverse product offerings, we are confident that ScripsAmerica will generate attractive growth in fiscal 2015 with significant improvement to the bottom line."
A live webcast of the Company's presentation at the Wall Street Analyst Forum's Institutional Investor Conference can be accessed from ScripsAmerica's website at: www.ScripsAmerica.com.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
CONTACT: Gregory FCA
Joe Hassett, 610-228-2110
joeh@gregoryfca.com
SOURCE: ScripsAmerica, Inc.
Copyright Business Wire 2015
(END) Dow Jones Newswires
March 18, 2015 08:00 ET (12:00 GMT)
Will Report Preliminary Fiscal 2014 Revenues of over $31 Million and Profitable Second Half of Year
Now Projecting First Quarter 2015 Net Income of over $400,000 on Revenues of more than $9.5 Million
TYSONS CORNER, Va.--(BUSINESS WIRE)--March 18, 2015--
ScripsAmerica, Inc. (OTCBB: SCRC), a leading provider of a range of specialty prescription and over the counter pharmaceuticals and medical supplies, today provided the investment community highlights of comments it will be making at the Wall Street Analyst Forum's 25th Annual Institutional Investor Conference about the Company's significantly improved financial results, outstanding growth of the specialty pharmacy business and rapid emergence of new revenue streams from diabetic medical supplies, PIMD International, Inc. and physician dispensing programs. This conference will be held at the University Club in New York, NY on Thursday, March 19, 2015.
-- The Company is currently projecting first quarter 2015 Net Income of over
$400,000 on revenue of over $9.5 million
-- The Company's preliminary financial reports indicate that revenue for the
year ended December 31, 2014 is expected to exceed $31 million
-- The Company's preliminary financial reports indicate that the Company
expects to report positive Net Income and EPS for the second half of 2014
-- As of December 31, 2014, it is anticipated that the Company will have
over $1.3 million in working capital, an approximately $3 million
improvement in liquidity over the course of fiscal 2104. In addition, the
Company has a $4 million working capital line of credit, providing all of
the liquidity and capital needed to execute its 2015 growth plan
-- The Company's PIMD International subsidiary has increased revenues from
$150,000 in January to $500,000 in February, with expectations that
revenues will remain at, if not exceed, February levels for the balance
of the year
-- The Company's newly launched diabetic medical supplies business has
enrolled over 700 patients, which will ramp a valuable new revenue stream
over the balance of the year
-- The Company has signed 2 Letters of Intent to purchase additional
pharmacies, which will supplement the revenues being generated by Main
Avenue Pharmacy
Mr. Schneiderman said, "Our goal is to generate value for our shareholders and the outstanding financial performance achieved in fiscal 2014, especially over the second half of the year, has created tremendous momentum heading into 2015, with current projections of a profitable first quarter of 2015. We have put in place a strategy that capitalizes on unique market niches where ScripsAmerica has a competitive advantage, and have built the infrastructure and management team that can effectively execute a plan to grow in these markets. While there will always be headwinds, because of our increasing financial strength and diverse product offerings, we are confident that ScripsAmerica will generate attractive growth in fiscal 2015 with significant improvement to the bottom line."
A live webcast of the Company's presentation at the Wall Street Analyst Forum's Institutional Investor Conference can be accessed from ScripsAmerica's website at: www.ScripsAmerica.com.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
CONTACT: Gregory FCA
Joe Hassett, 610-228-2110
joeh@gregoryfca.com
SOURCE: ScripsAmerica, Inc.
Copyright Business Wire 2015
(END) Dow Jones Newswires
March 18, 2015 08:00 ET (12:00 GMT)
